Literature DB >> 14094592

[ANTI-FACTOR VIII CIRCULATING ANTICOAGULANTS DURING HEMOPHILIA A. (NATURE AND MECHANISM OF ACTION)].

M GOUDEMAND, M FOUCAUT, A HUTIN, A PARQUET-GERNEZ.   

Abstract

Entities:  

Keywords:  ANTICOAGULANTS; CHROMATOGRAPHY; FACTOR VIII; GAMMA GLOBULIN; HEMOPHILIA; PRECIPITIN TESTS

Mesh：

Substances：

Year:  1963        PMID： 14094592

Source DB:  PubMed          Journal:  Nouv Rev Fr Hematol        ISSN： 0029-4810


× No keyword cloud information.
  6 in total

1.  [Development of inhibitors following long-term substitution of human antihemophilia globulin in severe hemophilia].

Authors:  F Bläker; K Fischer; G Landbeck
Journal:  Klin Wochenschr       Date:  1967-06-15

Review 2.  Hereditary disorders of blood coagulation due to defective and deficient synthesis of protein.

Authors:  D P Jackson
Journal:  Trans Am Clin Climatol Assoc       Date:  1971

3.  The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8.

Authors:  S S Shapiro
Journal:  J Clin Invest       Date:  1967-02       Impact factor: 14.808

4.  Immunologic studies in von Willebrand's disease. Evidence that the antihemophilic factor (AHF) produced after transfusions lacks an antigen associated with normal AHF and the inactive material produced by patients with classic hemophilia.

Authors:  B Bennett; O D Ratnoff; J Levin
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

5.  Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor.

Authors:  T S Zimmerman; O D Ratnoff; A E Powell
Journal:  J Clin Invest       Date:  1971-01       Impact factor: 14.808

6.  Congenital dysprothrombinemia: an inherited structural disorder of human prothrombin.

Authors:  S S Shapiro; J Martinez; R R Holburn
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.